UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Presentations
NTF2 regulates nuclear size in mammalian cells and may contribute
to altered nuclear size in melanoma
Authors*: Lidija D. Vukovic, Bradley A. Stohr, Dan L. Levy
Pres #: 475 Section: 22 Presentation Date/Time: Sunday, April 17: 1:00-5:00PM
Location:
Presentation Type: Poster Session
Stohr Lab Expertise: The research in my laboratory focuses on the telomere biology of human cancers.
Telomeres are nucleoprotein structures that protect the ends of linear chromosomes. Telomeres shorten with
each cell division, ultimately resulting in deprotection of the chromosome ends. Telomeric deprotection serves
a tumor-suppressive function by initiating senescence and/or apoptosis in inappropriately dividing cells.
However, deprotected telomeres frequently fuse together, resulting in genome instability that can promote
tumorigenesis. The cellular context determines whether it is the tumor-suppressive or tumor-promoting role
of the dysfunctional telomere that predominates. The long-term goal of my laboratory is to understand how
different types of telomere dysfunction provoke these diverse cellular responses. This knowledge will provide
insight into the origins and progression of human cancers and suggest novel strategies for telomere-based
therapeutic approaches.
http://labmed.ucsf.edu/about/faculty/pathology-bstohr.html
__________________________________________________________________________
Novel and shared neoantigen for glioma T-cell therapy derived from
histone 3 variant H3.3 K27M mutation
Authors*: Hideho Okada, Gary Kohanbash, Kaori Okada, Shuming Liu, Yi Lin, Sabine Mueller,
Ian F. Pollack, Angel M. Carcaboso, Yafei Hou
Pres #: 524 Section: 25 Presentation Date/Time: Sunday, April 17: 1:00-5:00PM
Location:
Presentation Type: Poster Session
Okada Lab Expertise: As a translational physician scientist, Dr. Okada and his lab are focused on development
of novel immunotherapeutic strategies for brain tumor patients. For example, Dr. Okada conducted one of
the first immune gene therapy trials in patients with malignant glioma. His lab was also the first to identify
and fully characterized cytotoxic T-lymphocyte epitopes for gliomas. Dr. Okada has also delineated the role
of an integrin receptor very late activation antigen-4 and chemokine CXCL10 in efficient trafficking of T-cells
to brain tumor sites. Dr. Okada has integrated these findings to develop a number of vaccine trials in both
adult and pediatric glioma patients. More recently, his group developed a novel chimeric antigen receptor
targeting glioblastoma cells, and are currently conducting a pilot trial.
http://neurosurgery.ucsf.edu/index.php/about_us_faculty_okada.html
*UCSF authors in bold
12